Increased IL-6 expression has been correlated with advanced disease stage and decreased survival of CRC patients, and several therapeutics targeting the IL6/STAT3 signaling pathway have been developed as a promising strategy for treatment of CRC (Waldner et al., 2012). Here, STAT3 is linked to colorectal carcinoma.